Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

SOLIGENIX, INC. Director's Dealing 2009

Feb 13, 2009

35119_dirs_2009-02-13_dab22335-ef62-4961-beaf-ba2baf16a986.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: DOR BIOPHARMA INC (DORB)
CIK: 0000812796
Period of Report: 2009-02-11

Reporting Person: SIGMA TAU FINANZIARIA SPA (10% Owner)
Reporting Person: SIGMA TAU INTERNATIONAL SA (10% Owner)
Reporting Person: Sigma-Tau America S.A. (10% Owner)
Reporting Person: Sigma-Tau Pharmaceuticals, Inc. (10% Owner)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2009-02-11 Common Stock P 25000000 $0.18 Acquired 41666667 Indirect

Footnotes

F1: Shares directly owned by Sigma-Tau Pharmaceuticals, Inc. (?Pharmaceuticals?). Pharmaceuticals is a direct wholly-owned subsidiary of Sigma-Tau America S.A. (?America?). America is a direct wholly-owned subsidiary of Sigma-Tau International S.A. (?International?). International is a direct wholly-owned subsidiary of Sigma-Tau Finanziaria S.p.A.